{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:38:16Z","timestamp":1791005896204,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nivolumab is an immune checkpoint inhibitor that blocks inhibitors of T-cell activation and blunts antitumor immunity and is used in the treatment of various cancers. However, immune checkpoint inhibitors have immune-related adverse effects on various organs due to promoting T-cell activity against host tissues by blocking inhibition of T-cell function. Although immune-related adverse effects including hepatitis, colitis, pneumonitis, dermatitis, nephritis, endocrinopathies, and hypophysitis are well recognized with established treatment guidelines, neuromuscular immune-related adverse effects are rare phenomena.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 55-year-old Asian (Japanese) woman was diagnosed with nivolumab-related myasthenia gravis with myositis and myocarditis. She had a past history of thymectomy for large thymoma with a high anti-acetylcholine receptor antibody level without any symptoms. Nivolumab was administered for the treatment of malignant melanoma. Creatine kinase levels began to rise 2\u00a0weeks after the administration, and abnormal neurological findings appeared 3\u00a0weeks after the administration. Ventricular arrhythmia, wide QRS complex, and dyssynchrony of the left ventricle also appeared. Intravenous immunoglobulin and corticosteroids were administered, and plasma exchange was performed. The patient required intensive care and prolonged mechanical ventilation with tracheostomy owing to weakness of the diaphragm; she was eventually weaned from the ventilator and discharged. Diaphragm ultrasound was used for the decision-making of the weaning strategy and evaluation of the diaphragmatic function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nivolumab-induced severe myasthenia gravis with myositis and myocarditis required intensive care and prolonged mechanical ventilation. Although immune checkpoint inhibitor-related myasthenia gravis is a rare adverse event, appropriate and prompt treatment is required because of its severity and rapid progression. Diaphragm ultrasound was useful not only in diagnosing diaphragm dysfunction and deciding the strategy for weaning from mechanical ventilation but also in evaluating the recovery of the diaphragmatic function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-022-03286-x","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T19:02:39Z","timestamp":1644778959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report"],"prefix":"10.1186","volume":"16","author":[{"given":"Yumi","family":"Saishu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8141-1850","authenticated-orcid":false,"given":"Yusuke","family":"Seino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"3286_CR1","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1001\/jama.2018.13995","volume":"320","author":"DB Johnson","year":"2018","unstructured":"Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018. JAMA. 2018;320:1702\u20133.","journal-title":"JAMA"},{"key":"3286_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","volume":"82","author":"D Makarious","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128\u201336.","journal-title":"Eur J Cancer"},{"key":"3286_CR3","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et\u00a0al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"3286_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111777","author":"N M\u00f6hn","year":"2019","unstructured":"M\u00f6hn N, Beutel G, Gutzmer R, Ivanyi P, Satzger I, Skripuletz T. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy\u2014review of the literature and future outlook. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8111777.","journal-title":"J Clin Med"},{"key":"3286_CR5","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et\u00a0al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375\u201391.","journal-title":"Ann Oncol"},{"key":"3286_CR6","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1016\/j.lpm.2018.10.009","volume":"47","author":"D Psimaras","year":"2018","unstructured":"Psimaras D. Neuromuscular complications of immune checkpoint inhibitors. Presse Med. 2018;47:e253\u20139.","journal-title":"Presse Med"},{"issue":"Suppl 2","key":"3286_CR7","first-page":"S74","volume":"24","author":"D Psimaras","year":"2019","unstructured":"Psimaras D, Velasco R, Birzu C, Tamburin S, Lustberg M, Bruna J, et\u00a0al. Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(Suppl 2):S74\u201385.","journal-title":"J Peripher Nerv Syst"},{"key":"3286_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, et\u00a0al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7:319.","journal-title":"J Immunother Cancer"},{"key":"3286_CR9","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","volume":"91","author":"M Touat","year":"2018","unstructured":"Touat M, Maisonobe T, Knauss S, Salem OBH, Hervier B, Aur\u00e9 K, et\u00a0al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018;91:e985\u201394.","journal-title":"Neurology"},{"key":"3286_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et\u00a0al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89:1127\u201334.","journal-title":"Neurology"},{"key":"3286_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ajem.2021.03.005","volume":"46","author":"DN Lipe","year":"2021","unstructured":"Lipe DN, Galvis-Carvajal E, Rajha E, Wechsler A, Gaeta S. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome. Am J Emerg Med. 2021;46:51\u20135.","journal-title":"Am J Emerg Med"},{"key":"3286_CR12","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMra1007236","volume":"366","author":"FD McCool","year":"2012","unstructured":"McCool FD, Tzelepis GE. Dysfunction of the diaphragm. N Engl J Med. 2012;366:932\u201342.","journal-title":"N Engl J Med"},{"key":"3286_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/MCC.0000000000000682","volume":"26","author":"M Dres","year":"2020","unstructured":"Dres M, Demoule A. Monitoring diaphragm function in the ICU. Curr Opin Crit Care. 2020;26:18\u201325.","journal-title":"Curr Opin Crit Care"},{"key":"3286_CR14","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1053\/j.jvca.2019.01.003","volume":"33","author":"L Vetrugno","year":"2019","unstructured":"Vetrugno L, Guadagnin GM, Barbariol F, Langiano N, Zangrillo A, Bove T. Ultrasound imaging for diaphragm dysfunction: a narrative literature review. J Cardiothorac Vasc Anesth. 2019;33:2525\u201336.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"3286_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00134-013-2823-1","volume":"39","author":"D Matamis","year":"2013","unstructured":"Matamis D, Soilemezi E, Tsagourias M, Akoumianaki E, Dimassi S, Boroli F, et\u00a0al. Sonographic evaluation of the diaphragm in critically ill patients. Technique and clinical applications. Intensive Care Med. 2013;39:801\u201310.","journal-title":"Intensive Care Med"},{"key":"3286_CR16","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00134-016-4245-3","volume":"42","author":"P Mayo","year":"2016","unstructured":"Mayo P, Volpicelli G, Lerolle N, Schreiber A, Doelken P, Vieillard-Baron A. Ultrasonography evaluation during the weaning process: the heart, the diaphragm, the pleura and the lung. Intensive Care Med. 2016;42:1107\u201317.","journal-title":"Intensive Care Med"},{"issue":"4","key":"3286_CR17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s00134-019-05892-8","volume":"46","author":"PR Tuinman","year":"2020","unstructured":"Tuinman PR, Jonkman AH, Dres M, Shi Z-H, Goligher EC, Goffi A, de Korte C, Demoule A, Heunks L. Respiratory muscle ultrasonography: methodology, basic and advanced principles and clinical applications in ICU and ED patients\u2014a narrative review. Intensive Care Med. 2020;46(4):594\u2013605. https:\/\/doi.org\/10.1007\/s00134-019-05892-8.","journal-title":"Intensive Care Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03286-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03286-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03286-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T19:02:54Z","timestamp":1644778974000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03286-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3286"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03286-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"30 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}